Short-term treatment with anti-CD44v7 antibody, but not CD44v4, restores the gut mucosa in established chronic dextran sulphate sodium (DSS)-induced colitis in mice

Clinical and Experimental Immunology

Volumn 142, Issue 2, 2005, Pages 260-267

  Farkas, Stefan ^a,d   Hornung, M ^a   Sattler, C ^a   Anthuber, M ^a   Gunthert, U ^b   Herfarth, H ^a   Schlitt, H J ^a   Geissler, E K ^a   Wittig, B M ^c  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY OF BASEL   (Switzerland)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

CD44 variant isoforms; CD44 variant therapy; Chronic inflammatory bowel disease

Indexed keywords

ANTIBODY; CD 44 VARIANT 4 ANTIBODY; CD 44 VARIANT 7 ANTIBODY; CD44V ANTIGEN; DEXTRAN SULFATE; ISOPROTEIN; MYELOPEROXIDASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CELL INTERACTION; CELL ISOLATION; CELL NUCLEUS; COLITIS; CONTROLLED STUDY; DIPLOIDY; DISEASE MARKER; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME ACTIVITY; EXTRAVASATION; FEMALE; FLUORESCENCE ANALYSIS; IMMUNE SYSTEM; INFLAMMATORY INFILTRATE; INTESTINE MUCOSA; LEUKOCYTE; MICROSCOPY; MONONUCLEAR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SHORT COURSE THERAPY; STATISTICAL SIGNIFICANCE; TIME SERIES ANALYSIS; UPREGULATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD44; CELL ADHESION; CHRONIC DISEASE; COLITIS; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; DOWN-REGULATION; ENDOTHELIAL CELLS; FEMALE; IMMUNITY, MUCOSAL; INTESTINAL MUCOSA; LEUKOCYTES; LYMPH NODES; LYMPHOCYTE ACTIVATION; MESENTERY; MICE; MICE, INBRED BALB C; PEROXIDASE; PROTEIN ISOFORMS;

EID: 27644503980     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2005.02911.x     Document Type: Article

References (38)

1. Rosemblatt M, Bono MR. Functional consequences of immune cell adhesion to endothelial cells. Curr Pharm Des 2004; 10:109-20.
2. Spiik AK, Ridderstad A, Axelsson LG, Midtvedt T, Bjork L, Pettersson S. Abrogated lymphocyte infiltration and lowered CD14 in dextran sulfate induced colitis in mice treated with p65 antisense oligonucleotides. Int J Colorectal Dis 2002; 17:223-32.
3. Farkas S, Herfarth H, Rossle M et al. Quantification of mucosal leucocyte endothelial cell interaction by in vivo fluorescence microscopy in experimental colitis in mice. Clin Exp Immunol 2001; 126:250-8.
4. Jalkanen S, Jalkanen M, Bargatze R, Tammi M, Butcher EC. Biochemical properties of glycoproteins involved in lymphocyte recognition of high endothelial venules in man. J Immunol 1988; 141:1615-23.
5. Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell 1990; 61:1303-13.
6. Foger N, Marhaba R, Zoller M. CD44 supports T cell proliferation and apoptosis by apposition of protein kinases. Eur J Immunol 2000; 30:2888-99.
7. Levesque MC, Haynes BF. Activated T lymphocytes regulate hyaluronan binding to monocyte CD44 via production of IL-2 and IFN-gamma. J Immunol 2001; 166:188-96.
8. Levesque MC, Haynes BF. TNFalpha and IL-4 regulation of hyaluronan binding to monocyte CD44 involves posttranslational modification of CD44. Cell Immunol 1999; 193:209-18.
9. Hodge-Dufour J, Noble PW, Horton MR et al. Induction of IL-12 and chemokines by hyaluronan requires adhesion-dependent priming of resident but not elicited macrophages. J Immunol 1997; 159:2492-500.
10. Konig H, Ponta H, Herrlich P. Coupling of signal transduction to alternative pre-mRNA splicing by a composite splice regulator. EMBO J 1998; 17:2904-13.
11. Arch R, Wirth K, Hofmann M et al. Participation in normal immune responses of a metastasis-inducing splice variant of CD44. Science 1992; 257:682-5.
12. Gunthert U, Hofmann M, Rudy W et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991; 65:13-24.
13. Gunthert U, Schwarzler C, Wittig B et al. Functional involvement of CD44, a family of cell adhesion molecules, in immune responses, tumour progression and haematopoiesis. Adv Exp Med 1998; 451:43-9.
14. Barbour AP, Reeder JA, Walsh MD, Fawcett J, Antalis TM, Gotley DC. Expression of the CD44v2-10 isoform confers a metastatic phenotype: importance of the heparan sulfate attachment site CD44v3. Cancer Res 2003; 63:887-92.
15. Seiter S, Arch R, Reber S et al. Prevention of tumor metastasis formation by anti-variant CD44. J Exp Med 1993; 177:443-55.
16. Wittig B, Seiter S, Foger N, Schwarzler C, Gunthert U, Zoller M. Functional activity of murine CD44 variant isoforms in allergic and delayed type hypersensitivity. Immunol Lett 1997; 57:217-23.
17. Wittig BM, Johansson B, Zoller M, Schwarzler C, Gunthert U. Abrogation of experimental colitis correlates with increased apoptosis in mice deficient for CD44 variant exon 7 (CD44v7). J Exp Med 2000; 191:2053-64.
18. Axelsson LG, Landstrom E, Goldschmidt TJ, Gronberg A, Bylund-Fellenius AC. Dextran sulfate sodium (DSS) induced experimental colitis in immunodeficient mice, effects in CD4(+)-cell depleted, athymic and NK-cell depleted SCID mice. Inflamm Res 1996; 45:181-91.
19. Kojouharoff G, Hans W, Obermeier F et al. Neutralization of tumour necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice. Clin Exp Immunol 1997; 107:353-8.
20. Dieleman LA, Ridwan BU, Tennyson GS, Beagley KW, Bucy RP, Elson CO. Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology 1994; 107:1643-52.
21. Obermeier F, Kojouharoff G, Hans W, Scholmerich J, Gross V, Falk W. Interferon-gamma (IFN-gamma)- and tumour necrosis factor (TNF)-induced nitric oxide as toxic effector molecule in chronic dextran sulphate sodium (DSS)-induced colitis in mice. Clin Exp Immunol 1999; 116:238-45.
22. Hamamoto N, Maemura K, Hirata I, Murano M, Sasaki S, Katsu K. Inhibition of dextran sulphate sodium (DSS)-induced colitis in mice by intracolonically administered antibodies against adhesion molecules (endothelial leucocyte adhesion molecule-1 (ELAM-1) or intercellular adhesion molecule-1 (ICAM-1). Clin Exp Immunol 1999; 117:462-8.
23. Obermeier F, Dunger N, Strauch UG et al. Contrasting activity of cytosinguanosin dinucleotide oligonucleotides in mice with experimental colitis. Clin Exp Immunol 2003; 134:217-24.
24. Harris AG, Hecht R, Peer F, Nolte D, Messmer K. An improved intravital microscopy system. Int J Microcirc Clin Exp 1997; 17:322-7.
25. Herfarth H, Brand K, Rath HC, Rogler G, Scholmerich J, Falk W. Nuclear factor-kappa B activity and intestinal inflammation in dextran sulphate sodium (DSS)-induced colitis in mice is suppressed by gliotoxin. Clin Exp Immunol 2000; 120:59-65.
26. Mackay CR. T-cell memory: the connection between function, phenotype and migration pathways. Immunol Today 1991; 12:189-92.
27. Siegelman MH, Stanescu D, Estess P. The CD44-initiated pathway of T-cell extravasation uses VLA-4 but not LFA-1 for firm adhesion. J Clin Invest 2000; 105:683-91.
28. DeGrendele HC, Estess P, Picker LJ, Siegelman MH. CD44 and its ligand hyaluronate mediate rolling under physiologic flow: a novel lymphocyte- endothelial cell primary adhesion pathway. J Exp Med 1996; 183:1119-30.
29. DeGrendele HC, Estess P, Siegelman MH. Requirement for CD44 in activated T cell extravasation into an inflammatory site. Science 1997; 278:672-5.
30. Von Andrian UH, Mempel TR. Homing and cellular traffic in lymph nodes. Nat Rev Immunol 2003; 3:867-78.
31. Marhaba R, Bourouba M, Zoller M. CD44v7 interferes with activation-induced cell death by up-regulation of anti-apoptotic gene expression. J Leukoc Biol 2003; 74:135-48.
32. Wittig B, Seiter S, Schmidt DS, Zuber M, Neurath M, Zoller M. CD44 variant isoforms on blood leukocytes in chronic inflammatory bowel disease and other systemic autoimmune diseases. Lab Invest 1999; 79:747-59.
33. Wittig BM, Zeitz M. The gut as an organ of immunology. Int J Colorectal Dis 2003; 18:181-7.
34. Termeer C, Averbeck M, Hara H et al. Targeting dendritic cells with CD44 monoclonal antibodies selectively inhibits the proliferation of naive CD4+ T-helper cells by induction of FAS-independent T-cell apoptosis. Immunology 2003; 109:32-40.
35. Wittig B, Schwarzler C, Fohr N, Gunthert U, Zoller M. Curative treatment of an experimentally induced colitis by a CD44 variant V7-specific antibody. J Immunol 1998; 161:1069-73.
36. Seiter S, Schmidt DS, Zoller M. The CD44 variant isoforms CD44v6 and CD44v7 are expressed by distinct leukocyte subpopulations and exert non-overlapping functional activities. Int Immunol 2000; 12:37-49.
37. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults, regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 2001; 107:1055-61.
38. Katagiri YU, Sleeman J, Fujii H et al. CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Res 1999; 59:219-26.